	US 12,403,175 B2
	Methods for treating pemphigus disorders
Peter Verheesen, Zwijnaarde (BE); and Patrick Dupuy, Zwijnaarde (BE)
Assigned to argenx BV, Zwijnaarde (BE)
Filed by argenx BV, Zwijnaarde (BE)
Filed on Jan. 8, 2021, as Appl. No. 17/144,481.
Claims priority of provisional application 62/960,647, filed on Jan. 13, 2020.
Claims priority of provisional application 62/958,543, filed on Jan. 8, 2020.
Prior Publication US 2021/0236596 A1, Aug. 5, 2021
Int. Cl. A61P 37/06 (2006.01); A61K 9/00 (2006.01); A61K 31/573 (2006.01); A61K 38/17 (2006.01); A61K 47/68 (2017.01); A61P 17/00 (2006.01)

CPC A61K 38/1709 (2013.01) [A61K 9/0019 (2013.01); A61K 31/573 (2013.01); A61K 47/6811 (2017.08); A61P 17/00 (2018.01); A61P 37/06 (2018.01)]

21 Claims

1. A method of treating pemphigus, comprising administering to a subject in need thereof an effective amount of a human neonatal Fc receptor (FcRn) antagonist, wherein the FcRn antagonist is efgartigimod, thereby treating pemphigus in the subject, wherein the subject has mild, moderate, or severe pemphigus as classified by the Pemphigus Disease Area Index (PDAI).